Remarks

Claims 1-32 are pending in the present application. Applicants would like to thank the Examiner for the allowance of Claims 1-20.

In an attempt to expedite the current application to grant, Applicants have limited the method claims to the specific indications listed in the dependent claims. Although the method claims have been limited, the amendment of the claims should not be considered as an admission of unpatentability of the deleted subject matter and Applicants reserve the right to pursue the methods of use for other indications in one or more continuation applications.

Claim 22 was amended to correct an inadvertent error. Clearly, Claim 22 should be dependent from Claim 21 and not Claim 18 since Claim 18 is a composition claim and not a method claim.

Claims 24 and 30 have been amended to provide proper dependency given the cancellation of Claims 23 and 29, respectively.

§112 Rejections

I. Claims 21, 25-27, 31 and 32 were rejected under 35 USC §112, 1st paragraph as being non-enabling.

Examiner indicated that Claims 22-24 and 28-30 would be allowable if rewritten in independent form. Applicant respectfully submits that the cancellation of Claims 25-26 and 31-32, together with the amendment of Claims 21 and 27 to include the limitations of Claims 23 and 29, respectively, renders this rejection moot.

Based on the amendments to Claims 21, 22, 24, 27 and 30, Applicant respectfully submits that Claims 1-22, 24, 27, 28 and 30 are in condition for allowance.

Respectfully Submitted:

Date: January 4, 2006

Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871